Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
The QIDP designation was introduced in 2012 to incentivize drug development in antiinfectives. QIDP came with several attractive features, such as prolongation of patent life, FDA expedited review and more. In addition, FDA made it quite easy to garner the label. As you can see, there is really no downside to Continue reading Prospecting for New Antibiotics
There are only 3 CDI drugs in wider clinical use: vancomycin, metronidazole, and fidaxomicin. They are from totally different classes and have almost nothing in common except for proven efficacy in C. difficile infection (CDI). Like vancomycin, the entire group of glycopeptide drugs seems to have good activity against C. Continue reading Quo Vadis, CDI Drugs?